Latest News about SNY
Recent news which mentions SNY
AbbVie's Pain Is Sanofi's and Regeneron's Gain
September 18, 2021
From Motley Fool
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
From Benzinga
These Promising Clinical Results Could Be Huge for Amgen Investors
September 11, 2021
From Motley Fool
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
September 11, 2021
From Motley Fool
3 Stocks to Watch in September
September 10, 2021
From Motley Fool
Could This Be Pfizer's Next Blockbuster Vaccine?
September 10, 2021
From Motley Fool
EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine
September 09, 2021
From Benzinga
Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?
September 09, 2021
From Motley Fool
2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)
September 09, 2021
From Motley Fool
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
September 09, 2021
Tickers
SNY
From Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
From Benzinga
From InvestorPlace
Why Kadmon Holdings Stock Is Rocketing Higher Today
September 08, 2021
From Motley Fool
From InvestorPlace
There’s an ETF sending one market haywire. A hedge-fund pro says bitcoin-like gains may come next.
September 08, 2021
From MarketWatch
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
September 08, 2021
From Benzinga
U.S. stock futures point to losses for Wall Street as delta worries linger
September 08, 2021
From MarketWatch
3 Hot Stocks to Buy in September
September 07, 2021
From Motley Fool
Got $5,000? These 2 Dividend Stocks Are Dirt Cheap Buys
September 02, 2021
From Motley Fool
3 Biotech Stocks That Are Too Cheap to Ignore
September 02, 2021
From Motley Fool
From Benzinga
4 Specialized AI Stocks to Buy for the Boom
August 31, 2021
From InvestorPlace
From Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
August 30, 2021
From Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
August 30, 2021
From Benzinga
Which Biotech Stock Will Shock the Market in 2022?
August 27, 2021
From Motley Fool
From Motley Fool
Is It Too Late to Buy Moderna Stock?
August 25, 2021
From Motley Fool
Is It Too Late to Buy Novavax Stock?
August 21, 2021
From Motley Fool
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.